51,263 Shares in Janux Therapeutics, Inc. $JANX Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 51,263 shares of the company’s stock, valued at approximately $711,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Janux Therapeutics in the fourth quarter worth $34,000. Caitong International Asset Management Co. Ltd purchased a new position in Janux Therapeutics during the fourth quarter valued at $51,000. Osaic Holdings Inc. grew its stake in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in Janux Therapeutics in the 4th quarter valued at $137,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Up 4.1%

Shares of JANX opened at $15.58 on Friday. The firm has a fifty day moving average price of $14.90 and a 200-day moving average price of $14.37. The firm has a market capitalization of $950.07 million, a P/E ratio of -8.47 and a beta of 2.52. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. Analysts predict that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JANX. UBS Group downgraded Janux Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $57.00 to $15.00 in a research note on Wednesday, April 15th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. JonesTrading reduced their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th. Guggenheim decreased their price target on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Barclays lowered shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the company from $29.00 to $14.00 in a research report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.08.

Insider Transactions at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the sale, the vice president owned 32,270 shares of the company’s stock, valued at $457,265.90. The trade was a 5.94% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.90% of the stock is owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.